CClinicalTrials.gg
RecruitingNCT07431788UMAHUpdated Mar 3, 2026

The Effect of Uterine Manipulator Use During Abdominal Hysterectomy on Postoperative Sexual Function

An interventional study of Uterine Manipulator and Conventional Abdominal Hysterectomy in Leiomyoma (Uterine Fibroids), Adenomyoma of Uterus and Uterine Bleeding, sponsored by Erkan Gol. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by Erkan Gol · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This prospective, single-center, randomized controlled trial aims to evaluate the effect of uterine manipulator use during total abdominal hysterectomy on postoperative female sexual function at 3 months, assessed by the Female Sexual Function Index (FSFI). Secondary outcomes include operative time, perioperative hemoglobin change, postoperative pain (VAS), hospital stay duration, and 30-day complications.

02

Conditions studied

  • Leiomyoma (Uterine Fibroids)
  • Adenomyoma of Uterus
  • Uterine Bleeding

Keywords

  • Hysterectomy
  • Uterin Manipulator
  • Female Sexual Function
  • FSFI
  • Randomized Controlled Trial
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Women aged ≥18 years
  • Planned total abdominal hysterectomy for benign indications
  • Sexually active within the last 4 weeks
  • Able to complete the Female Sexual Function Index (FSFI) questionnaire
  • Provided written informed consent

Exclusion criteria

Exclusion Criteria:

  • Gynecologic malignancy
  • Major additional pelvic reconstructive surgery
  • Severe psychiatric or neurologic disorder
  • Inability to complete follow-up assessments
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Abdominal Hysterectomy With Uterine Manipulator

    Total abdominal hysterectomy performed using a uterine manipulator.

    Procedure: Uterine Manipulator

  • Active comparator
    Abdominal Hysterectomy Without Uterine Manipulator

    Conventional total abdominal hysterectomy performed without uterine manipulator.

    Procedure: Conventional Abdominal Hysterectomy

Interventions

  • ProcedureUterine Manipulator

    Use of a uterine manipulator during total abdominal hysterectomy.

  • ProcedureConventional Abdominal Hysterectomy

    Total abdominal hysterectomy without uterine manipulator.

05

What researchers measure

Primary outcomes

  1. 3-Month Postoperative Female Sexual Function Index Total Score

    Female Sexual Function Index (FSFI) total score measured at 3 months after surgery. The FSFI is a validated 19-item questionnaire assessing sexual function across six domains. Total scores range from 2 to 36, with higher scores indicating better sexual function.

    Time frame: Assessed at postoperative month 3 (±2 weeks)

Secondary outcomes

  1. Operative Time

    Total operative duration measured in minutes from skin incision to completion of skin closure during total abdominal hysterectomy.

    Time frame: Measured intraoperatively from skin incision to skin closure (single assessment during surgery)

  2. Postoperative Pain Assessed by Visual Analog Scale (VAS)

    Postoperative pain intensity measured using a 10-cm Visual Analog Scale (VAS), where 0 indicates no pain and 10 indicates worst imaginable pain.

    Time frame: Assessed at 6 hours (±1 hour), 12 hours (±2 hours), and 24 hours (±2 hours) after surgery

  3. Change in Hemoglobin Level

    Difference between preoperative hemoglobin level and hemoglobin level measured 24 hours after surgery to assess perioperative blood loss.

    Time frame: Assessed at 6 hours (±1 hour), 12 hours (±2 hours), and 24 hours (±2 hours) after surgery

  4. Length of Hospital Stay

    Duration of hospitalization measured in days from the date of surgery until discharge.

    Time frame: From the date of surgery until hospital discharge, assessed up to 30 days postoperatively

  5. Postoperative Complications Within 30 Days

    Incidence of postoperative complications occurring within 30 days after surgery, classified according to the Clavien-Dindo grading system.

    Time frame: From the date of surgery until 30 days postoperatively (complications assessed up to 30 days after surgery)

06

Study locations

1 of 1 sites recruiting
  • Bakirkoy Dr. Sadi Konuk Training and Research Hospital
    Istanbul, Istanbul 34147, Turkey (Türkiye)
    Recruiting
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07431788
Lead sponsor
Erkan Gol
Responsible party
Erkan Gol (Principal Investigator, Bakirkoy Dr. Sadi Konuk Research and Training Hospital) — Sponsor-investigator
First posted
Feb 25, 2026
Start date
Mar 2, 2026
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Mar 3, 2026

Study contacts

Erkan Göl, MD
Contact
drerkangol@gmail.com
+905398517917
Erkan Göl, MD
principal investigator · University of Health Sciences, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion